Portfolio company Expedition Therapeutics completed a $115M Series B led by General Atlantic and dosed its first patient in a Phase 2 COPD trial.
Expedition Therapeutics is a biotech company developing treatments for inflammatory and respiratory diseases, including COPD
Expedition Therapeutics is a biotech company developing treatments for inflammatory and respiratory diseases, including COPD. The company's lead drug, EXPD-101, targets neutrophilic inflammation.